Efficacy and cost of a hepatocellular carcinoma screening program at an Australian teaching hospital.

摘要: Background and Aim:  Western countries are seeing an increasing prevalence of chronic viral hepatitis a subsequent rise in the incidence hepatocellular carcinoma (HCC). Screening patients at high risk HCC has become standard practice. The aim this study was to assess efficacy cost screening high-risk individuals for Australian tertiary hospital. Methods:  A retrospective review performed all who underwent Austin Hospital Melbourne between 1 October 1998 31 August 2004. carried out cirrhotic male non-cirrhotic with B virus. consisted 6-monthly alpha fetoprotein (AFP) measurements ultrasounds (US). Outcomes those had detected were followed up until 15 February 2007. Patients satisfying Milan criteria liver transplantation considered have potentially curable tumor. Costs diagnostic tests obtained from 2004 Medicare Benefits Schedule. Results:  total 268 patient records reviewed as part study. Chronic accounted 63% (n = 167). US median 6.5 months AFP 4.0 months. 22 (8.2%) 2.7% per year. These mean follow approximately 5.0 years after tumor detection. At time diagnosis, 17 10 alive conclusion up. Of these patients, six successfully transplanted, three treated radiological therapies one awaiting transplantation. program over period, including secondary investigations, $A300 568. $13 662 $17 680. Conclusion:  An effective can be provided through multi-disciplinary outpatient facility teaching hospital. Further stratification cohort may improve effectiveness program.